The Effect of Gelesis100 on the Pharmacokinetics of Metformin

NCT ID: NCT02524821

Last Updated: 2018-06-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2015-12-31

Brief Summary

The purpose of this study is to determine the effect of Gelesis100 on the absorption of metformin both with and without a meal.

Conditions

Healthy Overweight Obese

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

drugs only, fasted

1 x 850 mg metformin tablet, under fasting conditions.

Group Type: ACTIVE_COMPARATOR

Metformin

Intervention Type: DRUG

1 tablet of 850 mg

Gelesis100 plus drugs, fasted

3 x 0.75 g Gelesis100 capsules, followed 30 minutes later by the administration of 1 x 850 mg metformin tablet, under fasting conditions.

Group Type: EXPERIMENTAL

Gelesis100

Intervention Type: DEVICE

3 capsules each containing 0.75 mg

Metformin

Intervention Type: DRUG

1 tablet of 850 mg

drugs only, fed

1 x 850 mg metformin tablet, followed by the ingestion of a high-fat, high-caloric meal.

Group Type: ACTIVE_COMPARATOR

Metformin

Intervention Type: DRUG

1 tablet of 850 mg

Gelesis100 plus drugs, fed

3 x 0.75 g Gelesis100 capsules, followed by the ingestion of a high-fat, high-caloric meal, followed by the administration of 1 x 850 mg metformin tablet (fed conditions).

Group Type: ACTIVE_COMPARATOR

Gelesis100

Intervention Type: DEVICE

3 capsules each containing 0.75 mg

Metformin

Intervention Type: DRUG

1 tablet of 850 mg

Interventions

Gelesis100

3 capsules each containing 0.75 mg

Intervention Type: DEVICE

Metformin

1 tablet of 850 mg

Intervention Type: DRUG

Other Intervention Names

Glucophage

Eligibility Criteria

Inclusion Criteria

1. Male or female, non-smoker (no use of tobacco products within 3 months prior to screening), ≥ 22 and ≤ 65 years of age, with BMI ≥ 25.0 and ≤ 40.0 kg/m2.

2. Healthy as defined by:

1. the absence of clinically significant illness and surgery within 4 weeks prior to the first dosing (dosing refers to the administration of Gelesis100 or the substrate drugs, whichever comes first). Subjects vomiting within 24 hours pre-dose will be carefully evaluated for upcoming illness/disease. Inclusion pre-dosing is at the discretion of the Qualified Investigator.

2. the absence of clinically significant history of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.

3. the absence of history of lactic or metabolic acidosis.

4. the absence of clinically significant history of gastric or peptic ulcer.

5. the absence of clinically significant history or known presence of esophageal anatomic abnormalities (e.g., webs, diverticuli, rings), malabsorption, and gastroparesis.

6. the absence of history of gastric bypass, any other gastric surgery and intragastric balloon.

3. Females of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable contraceptive method throughout the study and for 30 days after the last medical device/substrate drug administration:

1. intra-uterine contraceptive device without hormone release system placed at least 4 weeks prior to medical device/substrate drug administration;

2. condom with intravaginally applied spermicide starting at least 14 days prior to medical device/substrate drug administration.

4. Capable of consent.

Exclusion Criteria

1. Any clinically significant abnormality or abnormal laboratory test results found during medical screening or positive test for hepatitis B, hepatitis C, or HIV found during medical screening.

2. Positive urine drug screen or urine cotinine test at screening.

3. History of allergic reactions to metformin, carboxymethylcellulose, citric acid, sodium stearyl fumarate, raw cane sugar, gelatin, titanium dioxide, or other related drugs or substances.

4. Positive pregnancy test at screening.

5. Breast-feeding.

6. Any reason which, in the opinion of the Qualified Investigator, would prevent the subject from participating in the study.

7. Clinically significant electrocardiogram (ECG) abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.

8. History of significant alcohol abuse within one year prior to screening or regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).

9. History of significant drug abuse within one year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP], and crack) within 1 year prior to screening.

10. Participation in a clinical trial involving the administration of an investigational or marketed drug within 30 days (90 days for biologics) prior to the first dosing or concomitant participation in an investigational study involving no drug administration.

11. Use of medication other than topical products without significant systemic absorption:

1. prescription medication within 14 days prior to the first dosing;

2. over-the-counter products including natural health products (e.g., food supplements and herbal supplements) within 7 days prior to the first dosing, with the exception of the occasional use of acetaminophen (up to 2 g daily);

3. a depot injection or an implant of any drug within 3 months prior to the first dosing.

12. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening) of 50 mL to 499 mL within 30 days, or more than 499 mL within 56 days prior to the first dosing.

13. Hemoglobin <128 g/L (males) and <115 g/L (females) and hematocrit <0.37 L/L (males) and <0.32 L/L (females) at screening.

14. Subject with a small appetite or who would have difficulty to complete a high-fat, high-caloric meal, or to drink a large amount of liquid.

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Gelesis, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Audet

Role: PRINCIPAL_INVESTIGATOR

Quebec City, Quebec Canada

Locations

Québec, Quebec, Canada

Countries

Canada

Other Identifiers

GS-100-005

Identifier Type: -

Identifier Source: org_study_id